Holen Sie sich die Stockscreener-App
76.50
0.09%
-0.07
Handel nachbörslich:
76.50
Schlusskurs vom Vortag:
$76.57
Offen:
$76.6
24-Stunden-Volumen:
1.62M
Relative Volume:
1.81
Marktkapitalisierung:
$14.96B
Einnahmen:
$579.96M
Nettoeinkommen (Verlust:
$-729.89M
KGV:
-20.42
EPS:
-3.7459
Netto-Cashflow:
$-452.02M
1W Leistung:
-3.62%
1M Leistung:
-4.48%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$75.95
$78.25
1-Wochen-Bereich:
$75.02
$80.55
52-Wochen-Spanne:
$75.02
$89.49
Bio Rad Laboratories Inc Stock (BBIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO
Compare BBIO vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bio Rad Laboratories Inc
|
76.50 | 16.21B | 579.96M | -729.89M | -452.02M | -3.7459 |
ABT
Abbott Laboratories
|
110.47 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
312.19 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.18 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
48.37 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.82 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Aktie (BBIO) Neueste Nachrichten
Return on invested capital % of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA - TradingView
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? - Yahoo Finance
Bio-Rad (BIO) Quarter in Focus: Profit Per Share Clears Its Benchmark for the Current Session - vinanet.vn
Bio-Rad Laboratories Inc (BIO) Shares Surge 3.4% -- What GF Scor - GuruFocus
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building? - Yahoo Finance
Westport Asset Management Inc. Invests $881,000 in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at $365.68 By Investing.com - Investing.com Nigeria
Bio-Rad Laboratories (NYSE:BIO) Reaches New 12-Month HighShould You Buy? - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at $365.68 - Investing.com
Bio Rad Laboratories Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
S&P 500 Futures Decline In Premarket Trading; Bio-Rad Labs A, Fabrinet Lag - Moomoo
Sickle Cell Anemia Testing & Screening Industry Trends & Growth - SNS Insider
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Challenging Market with Innovative Diagnostics - DirectorsTalk Interviews
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher. - The Motley Fool
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost? - Yahoo Finance
Bio-Rad Laboratories (NYSE:BIO) Upgraded to Hold at Zacks Research - MarketBeat
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
First Trust Advisors LP Has $424,000 Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock forecasts - Yahoo Finance UK
Bio Rad Laboratories (BIO) Issues Flat Revenue Guidance, Is It Too Far Above Fair Value? - Sahm
Bio-Rad (BIO) Q2 2026 Earnings Call Transcript - aol.com
Bio-Rad Laboratories (NYSE:BIO) Hits New 52-Week HighHere's What Happened - MarketBeat
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock - Yahoo Finance
Bio-Rad Laboratories (BIO) Stock Analysis: Exploring a Potentially Overvalued Healthcare Giant - DirectorsTalk Interviews
Bio Rad Laboratories (BIO) Earnings And Guidance Put Fair Value Back In Focus - Yahoo Finance
Technical Reactions to BIO Trends in Macro Strategies - Stock Traders Daily
Assenagon Asset Management S.A. Acquires 85,393 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at 352.86 USD - Investing.com
Bio Rad Laboratories Inc (BIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
US$329That's What Analysts Think Bio-Rad Laboratories, Inc. (NYSE:BIO) Is Worth After These Results - 富途牛牛
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $390 - Moomoo
Bio-Rad's FCPA Review Gets Picked Over at Trial - Law.com
Bio-Rad Laboratories, Inc. $BIO Shares Bought by California State Teachers Retirement System - marketbeat.com
BIO-RAD LABORATORIES, INC. : WELLS FARGO RAISES TARGET PRICE TO $330 FROM $310 - webull.com
BIO Maintained by Citigroup -- Price Target Raised to $330 - GuruFocus
Is Bio-Rad Laboratories Inc (BIO) Overvalued After 4.5% Rally? G - GuruFocus
Citigroup Increases Bio-Rad Laboratories (NYSE:BIO) Price Target to $330.00 - MarketBeat
BIO Maintains Rating by Wells Fargo -- Price Target Raised to $3 - GuruFocus
Royal Bank Of Canada Forecasts Strong Price Appreciation for Bio-Rad Laboratories (NYSE:BIO) Stock - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Sets New 52-Week High on Earnings Beat - marketbeat.com
Bio-Rad Laboratories, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
BIO SWOT Analysis: Financial Resilience Amidst Market Challenges Revealed in 10-Q Filing - GuruFocus
AUG 04 (REUTERS)BIO-RAD Q2 EPS USD 13.85. - Moomoo
Amundi Has $10.81 Million Holdings in Bio-Rad Laboratories, Inc. $BIO - marketbeat.com
Bio-Rad Earnings: Modest Sequential Improvement, but Full-Year Guidance Ranges Remain Wide - Morningstar
Bio-Rad Laboratories Inc (BIO) (Q2 2026) Earnings Call Highlights: Digital PCR Surges 20%+ as ... By GuruFocus - Investing.com Canada
BIO Looks 4.8% Overvalued on GF Value™ Amid Restructuring Plans - GuruFocus
Bio-Rad Laboratories Q2 Earnings Call Highlights - MarketBeat
Bio-Rad: Q2 Earnings Snapshot - Barchart.com
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bio Rad Laboratories Inc-Aktie (BBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Aug 19 '26 |
Sale |
84.03 |
10,000 |
840,257 |
505,686 |
0.10%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):